Cil Laboratories Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 3.71 Cr
as on 15-12-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.02 M
as on 15-12-2024
- Satisfied Charges ₹ 6.00 M
as on 15-12-2024
- Revenue -99.79%
(FY 2022)
- Profit -638.13%
(FY 2022)
- Ebitda -107.57%
(FY 2022)
- Net Worth 1354.08%
(FY 2022)
- Total Assets -15.55%
(FY 2022)
About Cil Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.71 Cr.
The company currently has active open charges totaling ₹5.02 M. The company has closed loans amounting to ₹6.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sharad Agarwal, Siddharth Tibrewal, and Santanu Bakshi serve as directors at the Company.
- CIN/LLPIN
U36999WB2016PTC216162
- Company No.
216162
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2016
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cil Laboratories Private Limited offer?
Cil Laboratories Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Cil Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santanu Bakshi  | Director | 20-Mar-2017 | Current |
| Sharad Agarwal | Director | 30-Mar-2023 | Current |
| Siddharth Tibrewal | Director | 09-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Cil Laboratories.
Cil Laboratories Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 99.79% decrease. The company also saw a substantial fall in profitability, with a 638.13% decrease in profit. The company's net worth Soared by an impressive increase of 1354.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cil Laboratories?
In 2023, Cil Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Showering Snow Private LimitedActive 5 years 3 months
Sharad Agarwal and Santanu Bakshi are mutual person
- Unifour Comercio Private LimitedActive 7 years 11 months
Sharad Agarwal and Santanu Bakshi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 04 Nov 2022 | ₹4.00 M | Open |
Others Creation Date: 21 May 2022 | ₹1.02 M | Open |
Others Creation Date: 05 Jan 2019 | ₹6.00 M | Satisfied |
How Many Employees Work at Cil Laboratories?
Cil Laboratories has a workforce of 0 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cil Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cil Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
